Keywords: Roche, Plexxikon, PLX4032, metastatic melanoma, Bristol-Myers Squibb, Ipilimumab

Roche and Plexxikon’s PLX4032 shows 81% response in metastatic melanoma patients in Ph I trial

Article | 26 August 2010

Print This

Data from the Phase I clinical trial of PLX4032 (RG7204), has confirmed that treatment of metastatic melanoma patients with the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in